GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3

GH Research PLC remains well-capitalized with $280.7 million in cash, supporting its lead candidate GH001 for Treatment-Resistant Depression. GHRS's investment thesis centers on replicating strong Phase 2b efficacy for GH001 in a pivotal Phase 3 trial, with rapid, durable antidepressant effects and operational simplicity. The FDA has cleared GH001 for U.S. clinical investigation, positioning GHRS for a global Phase 3 program starting in 2026 without immediate capital constraints.